oral flouxetine 20 mg for 24 weeks will be given to patient whom randomised to intervention group

2 trials

Sponsors

Arak University of Medical Science,Office of Vice Chancellor for Research

Conditions

Multiple Sclerosis. Demyelinating diseases of the central nervous systemmultiple sclerosis. Demyelinating diseases of the central nervous system

Phase 3

Fluxetine AND Multiple Sclerosis

Active, not recruitingIRCT2014052417811N2

Arak University of Medical Science,Office of Vice Chancellor for Researchmultiple sclerosis. Demyelinating diseases of the central nervous system

Start: 2013-07-02Target: 58Updated: 2018-02-22

fluoxetine AND Multiple sclerosis

Active, not recruitingIRCT2014062017811N3

Arak University of Medical Science,Office of Vice Chancellor for ResearchMultiple Sclerosis. Demyelinating diseases of the central nervous system

Start: 2013-07-02Target: 60Updated: 2018-02-22